BMTI Share Price

Open 9.49 Change Price %
High 9.51 1 Day 0.06 0.64
Low 9.42 1 Week 0.00 0.00
Close 9.49 1 Month 0.00 0.00
Volume 250541 1 Year 0.00 0.00
52 Week High 38.85
52 Week Low 0.00
BMTI Important Levels
Resistance 2 9.57
Resistance 1 9.54
Pivot 9.47
Support 1 9.44
Support 2 9.41
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI)

BMTI Technical Analysis 5
As on 28th Feb 2013 BMTI Share Price closed @ 9.49 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.67 & Strong Buy for SHORT-TERM with Stoploss of 8.10 we also expect STOCK to react on Following IMPORTANT LEVELS.
BMTI Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BMTI Other Details
Segment EQ
Market Capital 113994632.00
Sector Health Care Medical/Dental Instruments
Industry
Offical website
BMTI Address
BMTI
N/A
BMTI Latest News
Interactive Technical Analysis Chart BioMimetic Therapeutics, Inc. ( BMTI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioMimetic Therapeutics, Inc.
BMTI Business Profile
BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company’s Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company’s product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.